Maven Securities LTD Invests $761,000 in iShares Biotechnology ETF $IBB

Maven Securities LTD purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 6,014 shares of the financial services provider’s stock, valued at approximately $761,000.

Several other institutional investors also recently made changes to their positions in the stock. Citigroup Inc. increased its holdings in shares of iShares Biotechnology ETF by 27.0% during the 2nd quarter. Citigroup Inc. now owns 4,073,967 shares of the financial services provider’s stock worth $515,398,000 after buying an additional 865,823 shares during the last quarter. JPMorgan Chase & Co. grew its position in iShares Biotechnology ETF by 74.2% during the second quarter. JPMorgan Chase & Co. now owns 833,196 shares of the financial services provider’s stock valued at $105,408,000 after acquiring an additional 355,000 shares during the period. Bronte Capital Management Pty Ltd. increased its stake in iShares Biotechnology ETF by 12.6% during the second quarter. Bronte Capital Management Pty Ltd. now owns 295,346 shares of the financial services provider’s stock worth $37,000 after acquiring an additional 32,947 shares during the last quarter. Employees Retirement System of Texas purchased a new position in shares of iShares Biotechnology ETF in the 2nd quarter worth about $25,049,000. Finally, Jones Financial Companies Lllp raised its holdings in shares of iShares Biotechnology ETF by 763.3% in the 1st quarter. Jones Financial Companies Lllp now owns 151,265 shares of the financial services provider’s stock worth $19,347,000 after purchasing an additional 133,744 shares during the period. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Trading Down 1.7%

Shares of NASDAQ:IBB opened at $167.09 on Wednesday. iShares Biotechnology ETF has a 1 year low of $107.43 and a 1 year high of $174.40. The stock has a 50-day simple moving average of $160.39 and a 200-day simple moving average of $142.90.

iShares Biotechnology ETF Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 19th. Shareholders of record on Tuesday, September 16th were paid a dividend of $0.0828 per share. This represents a $0.33 annualized dividend and a yield of 0.2%. The ex-dividend date was Tuesday, September 16th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.